Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news


16 May 2020, Naarden, The Netherlands - Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as its initiating director of operations have announced the...

BGV Fellowship

Location: Naarden, The Netherlands Duration: 6-9 months About BGV Since our inception in 2006, BGV has raised four early-stage biotech funds totaling over €250 million in capital. Our portfolio is focused on novel therapeutics across different treatment modalities and...

Next events

BioVaria 11-12 May

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe. This unique event brings together Europe‘s leading tech transfer professionals, innovators...

Venture Challenge 22 April, 2022

FIRST Fund's Rianne Ellenbroek joins the jury for Venture Challenge taking place on 22 April 2022 in Den Haag. During the Venture Challenge, researchers are guided in setting up a venture plan, in which a scientific breakthrough in the life sciences is converted into...

Latest investments

Subscribe to BGV news updates

Join our mailing list to receive the latest news and updates from our team.

Privacy Policy

Please check your email to complete your subscription.